Search Results for: UBASH3A

108 interactions involving UBASH3A - ubiquitin associated and SH3 domain containing A found:

Sort by: Symbol Number of Pathways Number of Drugs Number of Diseases
Novel Symbol Description Pathways Hide Drugs Hide Diseases Hide
DTX3 deltex E3 ubiquitin ligase 3
EHMT2 euchromatic histone lysine methyltransferase 2
  • Senescence-Associated Secretory Phenotype (SASP)
  • PKMTs methylate histone lysines
  • ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression
  • Regulation of TP53 Activity through Methylation
  • RNA Polymerase I Transcription Initiation
  • Transcriptional Regulation by VENTX
  • Transcriptional Regulation by E2F6
  • Regulation of endogenous retroelements by the Human Silencing Hub (HUSH) complex
FADS6 fatty acid desaturase 6
FAM83A family with sequence similarity 83 member A
  • Signaling by EGFR
FGFR1OP2 FGFR1 oncogene partner 2
  • Signaling by cytosolic FGFR1 fusion mutants
  • Signaling by FGFR1 in disease
GFAP glial fibrillary acidic protein
  • Nuclear signaling by ERBB4
  • Chaperone Mediated Autophagy
  • Alexander disease
GOLGA6L9 golgin A6 family like 9
HSP90AA1 heat shock protein 90 alpha family class A member 1
  • Signaling by ERBB2
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation
  • DDX58/IFIH1-mediated induction of interferon-alpha/beta
  • vRNP Assembly
  • Regulation of actin dynamics for phagocytic cup formation
  • eNOS activation
  • Regulation of PLK1 Activity at G2/M Transition
  • Scavenging by Class F Receptors
  • Scavenging by Class F Receptors
  • HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand
  • HSF1 activation
  • Attenuation phase
  • HSF1-dependent transactivation
  • Loss of Nlp from mitotic centrosomes
  • Recruitment of mitotic centrosome proteins and complexes
  • Loss of proteins required for interphase microtubule organization from the centrosome
  • Recruitment of NuMA to mitotic centrosomes
  • Sema3A PAK dependent Axon repulsion
  • VEGFA-VEGFR2 Pathway
  • VEGFA-VEGFR2 Pathway
  • VEGFR2 mediated vascular permeability
  • Uptake and function of diphtheria toxin
  • PIWI-interacting RNA (piRNA) biogenesis
  • Anchoring of the basal body to the plasma membrane
  • Constitutive Signaling by EGFRvIII
  • Regulation of necroptotic cell death
  • Interleukin-4 and Interleukin-13 signaling
  • Neutrophil degranulation
  • The role of GTSE1 in G2/M progression after G2 checkpoint
  • AURKA Activation by TPX2
  • Downregulation of ERBB2 signaling
  • ESR-mediated signaling
  • Extra-nuclear estrogen signaling
  • RHOBTB2 GTPase cycle
  • Estrogen-dependent gene expression
  • Chaperone Mediated Autophagy
  • Constitutive Signaling by Overexpressed ERBB2
  • Aggrephagy
  • Drug-mediated inhibition of ERBB2 signaling
  • Signaling by ERBB2 KD Mutants
  • Resistance of ERBB2 KD mutants to trastuzumab
  • Resistance of ERBB2 KD mutants to sapitinib
  • Resistance of ERBB2 KD mutants to tesevatinib
  • Resistance of ERBB2 KD mutants to neratinib
  • Resistance of ERBB2 KD mutants to osimertinib
  • Resistance of ERBB2 KD mutants to afatinib
  • Resistance of ERBB2 KD mutants to AEE788
  • Resistance of ERBB2 KD mutants to lapatinib
  • Signaling by ERBB2 ECD mutants
  • Signaling by ERBB2 TMD/JMD mutants
  • Drug resistance in ERBB2 TMD/JMD mutants
  • Potential therapeutics for SARS
  • SARS-CoV-2 activates/modulates innate and adaptive immune responses
  • Assembly and release of respiratory syncytial virus (RSV) virions
  • Respiratory syncytial virus genome replication
  • Rifabutin
  • Nedocromil
  • 9-Butyl-8-(2,5-Dimethoxy-Benzyl)-9h-Purin-6-Ylamine
  • Geldanamycin
  • 8-(2-Chloro-3,4,5-Trimethoxy-Benzyl)-2-Fluoro-9-Pent-4-Ylnyl-9h-Purin-6-Ylamine
  • 9-Butyl-8-(3,4,5-Trimethoxybenzyl)-9h-Purin-6-Amine
  • 4-(1,3-Benzodioxol-5-Yl)-5-(5-Ethyl-2,4-Dihydroxyphenyl)-2h-Pyrazole-3-Carboxylic Acid
  • 8-(2,5-Dimethoxy-Benzyl)-2-Fluoro-9h-Purin-6-Ylamine
  • 8-(2,5-Dimethoxy-Benzyl)-2-Fluoro-9-Pent-9h-Purin-6-Ylamine
  • 9-Butyl-8-(2-Chloro-3,4,5-Trimethoxy-Benzyl)-9h-Purin-6-Ylamine
  • 4-(1h-Imidazol-4-Yl)-3-(5-Ethyl-2,4-Dihydroxy-Phenyl)-1h-Pyrazole
  • 9-Butyl-8-(3-Methoxybenzyl)-9h-Purin-6-Amine
  • 9-Butyl-8-(4-Methoxybenzyl)-9h-Purin-6-Amine
  • 9-Butyl-8-(2,5-Dimethoxy-Benzyl)-2-Fluoro-9h-Purin-6-Ylamine
  • Quercetin
  • 8-Benzo[1,3]Dioxol-,5-Ylmethyl-9-Butyl-2-Fluoro-9h-Purin-6-Ylamine
  • 8-(2-Chloro-3,4,5-Trimethoxy-Benzyl)-9-Pent-4-Ylnyl-9h-Purin-6-Ylamine
  • N-[4-(AMINOSULFONYL)BENZYL]-5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-1H-PYRAZOLE-4-CARBOXAMIDE
  • Tanespimycin
  • SNX-5422
  • N-(4-ACETYLPHENYL)-5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-1H-PYRAZOLE-4-CARBOXAMIDE
  • 4-CHLORO-6-(4-{4-[4-(METHYLSULFONYL)BENZYL]PIPERAZIN-1-YL}-1H-PYRAZOL-5-YL)BENZENE-1,3-DIOL
  • 5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-N-ETHYL-4-PIPERAZIN-1-YL-1H-PYRAZOLE-3-CARBOXAMIDE
  • 5-(5-chloro-2,4-dihydroxyphenyl)-N-ethyl-4-[4-(morpholin-4-ylmethyl)phenyl]isoxazole-3-carboxamide
  • 5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-N-ETHYL-4-(4-METHOXYPHENYL)ISOXAZOLE-3-CARBOXAMIDE
  • 2-amino-4-[2,4-dichloro-5-(2-pyrrolidin-1-ylethoxy)phenyl]-N-ethylthieno[2,3-d]pyrimidine-6-carboxamide
  • 4-CHLORO-6-(4-PIPERAZIN-1-YL-1H-PYRAZOL-5-YL)BENZENE-1,3-DIOL
  • (3E)-3-[(phenylamino)methylidene]dihydrofuran-2(3H)-one
  • 6-(3-BROMO-2-NAPHTHYL)-1,3,5-TRIAZINE-2,4-DIAMINE
  • 3-({2-[(2-AMINO-6-METHYLPYRIMIDIN-4-YL)ETHYNYL]BENZYL}AMINO)-1,3-OXAZOL-2(3H)-ONE
  • N-[(2-AMINO-6-METHYLPYRIMIDIN-4-YL)METHYL]-3-{[(E)-(2-OXODIHYDROFURAN-3(2H)-YLIDENE)METHYL]AMINO}BENZENESULFONAMIDE
  • 5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-N-ETHYL-4-(4-METHOXYPHENYL)-1H-PYRAZOLE-3-CARBOXAMIDE
  • 4-bromo-6-(6-hydroxy-1,2-benzisoxazol-3-yl)benzene-1,3-diol
  • CCT-018159
  • 4-chloro-6-{5-[(2-morpholin-4-ylethyl)amino]-1,2-benzisoxazol-3-yl}benzene-1,3-diol
  • 8-(6-BROMO-BENZO[1,3]DIOXOL-5-YLSULFANYL)-9-(3-ISOPROPYLAMINO-PROPYL)-ADENINE
  • 4-methyl-7,8-dihydro-5H-thiopyrano[4,3-d]pyrimidin-2-amine
  • (5E,7S)-2-amino-7-(4-fluoro-2-pyridin-3-ylphenyl)-4-methyl-7,8-dihydroquinazolin-5(6H)-one oxime
  • 8-BENZO[1,3]DIOXOL-,5-YLMETHYL-9-BUTYL-9H-
  • 4-{[(2R)-2-(2-methylphenyl)pyrrolidin-1-yl]carbonyl}benzene-1,3-diol
  • 2-(1H-pyrrol-1-ylcarbonyl)benzene-1,3,5-triol
  • 2-[(2-methoxyethyl)amino]-4-(4-oxo-1,2,3,4-tetrahydro-9H-carbazol-9-yl)benzamide
  • 4-(2-methoxyethoxy)-6-methylpyrimidin-2-amine
  • 4-(2,4-dichlorophenyl)-5-phenyldiazenyl-pyrimidin-2-amine
  • 3,6-DIAMINO-5-CYANO-4-(4-ETHOXYPHENYL)THIENO[2,3-B]PYRIDINE-2-CARBOXAMIDE
  • 2-AMINO-4-(2,4-DICHLOROPHENYL)-N-ETHYLTHIENO[2,3-D]PYRIMIDINE-6-CARBOXAMIDE
  • Copper
  • Polaprezinc
  • Alvespimycin
HSP90B1 heat shock protein 90 beta family member 1
  • Trafficking and processing of endosomal TLR
  • Scavenging by Class A Receptors
  • Scavenging by Class A Receptors
  • ATF6 (ATF6-alpha) activates chaperone genes
  • Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
  • Interleukin-4 and Interleukin-13 signaling
  • Post-translational protein phosphorylation
  • Rifabutin
  • 2-Chlorodideoxyadenosine
  • Geldanamycin
  • Diglyme
  • N-Ethyl-5'-Carboxamido Adenosine
  • Radicicol
  • METHYL 3-CHLORO-2-{3-[(2,5-DIHYDROXY-4-METHOXYPHENYL)AMINO]-3-OXOPROPYL}-4,6-DIHYDROXYBENZOATE
  • 2-(3-AMINO-2,5,6-TRIMETHOXYPHENYL)ETHYL 5-CHLORO-2,4-DIHYDROXYBENZOATE
  • Copper
HSPD1 heat shock protein family D (Hsp60) member 1
  • Mitochondrial protein import
  • Mitochondrial protein import
  • TFAP2A acts as a transcriptional repressor during retinoic acid induced cell differentiation
  • Mitochondrial protein degradation
  • Mitochondrial unfolded protein response (UPRmt)
  • Copper
  • Hypomyelinating leukodystrophy (HLD); Pelizaeus-Merzbacher disease (PMD)
  • Hereditary spastic paraplegia (SPG)
IKBKG inhibitor of nuclear factor kappa B kinase regulatory subunit gamma
  • Activation of NF-kappaB in B cells
  • Activation of NF-kappaB in B cells
  • ER-Phagosome pathway
  • NOD1/2 Signaling Pathway
  • TICAM1, RIP1-mediated IKK complex recruitment
  • RIP-mediated NFkB activation via ZBP1
  • Downstream TCR signaling
  • FCERI mediated NF-kB activation
  • TAK1-dependent IKK and NF-kappa-B activation
  • activated TAK1 mediates p38 MAPK activation
  • JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1
  • SUMOylation of immune response proteins
  • Regulation of TNFR1 signaling
  • TNFR1-induced NF-kappa-B signaling pathway
  • IKBKB deficiency causes SCID
  • IKBKG deficiency causes anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) (via TLR)
  • IkBA variant leads to EDA-ID
  • CLEC7A (Dectin-1) signaling
  • MAP3K8 (TPL2)-dependent MAPK1/3 activation
  • Ub-specific processing proteases
  • Ovarian tumor domain proteases
  • Interleukin-1 signaling
  • TRAF6 mediated NF-kB activation
  • NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10
  • IRAK1 recruits IKK complex
  • IKK complex recruitment mediated by RIP1
  • SARS-CoV-2 activates/modulates innate and adaptive immune responses
  • IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation
  • Regulation of NF-kappa B signaling
  • PKR-mediated signaling
  • SLC15A4:TASL-dependent IRF5 activation
  • Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells
  • Modulation of host responses by IFN-stimulated genes
  • AGRO100
  • Tarenflurbil
  • Incontinentia pigmenti
  • Ectodermal dysplasia associated immunodeficiency (EDA-ID), including the following two diseases: NF-kappa-B essential modulator (NEMO) defect; Inhibitor of kappa-B (I-kappa-B) defect
  • Osteoporosis, lymphedema, anhydrotic ectodermal dysplasia with immunodeficiency (OLEDAID); Ectodermal dysplasia, anhidrotic, with immunodeficiency, osteopetrosis, and lymphedema
ISY1-RAB43 ISY1-RAB43 readthrough
  • Formation of TC-NER Pre-Incision Complex
  • Transcription-Coupled Nucleotide Excision Repair (TC-NER)
  • Dual incision in TC-NER
  • Gap-filling DNA repair synthesis and ligation in TC-NER
  • mRNA Splicing - Major Pathway
KCNE1 potassium voltage-gated channel subfamily E regulatory subunit 1
  • Phase 3 - rapid repolarisation
  • Phase 2 - plateau phase
  • Enflurane
  • Promethazine
  • Miconazole
  • Azimilide
  • Long QT syndrome, including: Romano-Ward syndrome; Jervell and Lange-Nielsen syndrome (JLNS)
KCTD1 potassium channel tetramerization domain containing 1
  • Negative regulation of activity of TFAP2 (AP-2) family transcription factors
KIAA0408 KIAA0408
KPRP keratinocyte proline rich protein
  • Differentiation of Keratinocytes in Interfollicular Epidermis in Mammalian Skin
KRT14 keratin 14
  • Type I hemidesmosome assembly
  • Keratinization
  • Formation of the cornified envelope
  • Differentiation of Keratinocytes in Interfollicular Epidermis in Mammalian Skin
  • Developmental Lineage of Mammary Gland Myoepithelial Cells
  • Zinc
  • Zinc acetate
  • Epidermolysis bullosa simplex, including: Epidermolysis bullosa simplex, Dowling-Meara type (EBS-DM); Epidermolysis bullosa simplex, Koebner type (EBS-K); Epidermolysis bullosa simplex, Weber-Cockayne type (EBS-WC); Epidermolysis bullosa simplex with mottled pigmentation (EBS-MP); Epidermolysis bullosa simplex with migratory circinate erythema; Epidermolysis bullosa simplex, recessive; Epidermolysis bullosa, lethal acantholytic
  • Dermatopathia pigmentosa reticularis
  • Naegeli-Franceschetti-Jadassohn syndrome
KRT31 keratin 31
  • Keratinization
  • Formation of the cornified envelope
KRT32 keratin 32
  • Keratinization
  • Formation of the cornified envelope
KRT35 keratin 35
  • Keratinization
  • Formation of the cornified envelope

Page 2 out of 6 pages